Gillian barre syndrome

Reading File

Finding Sources

Searching PubMed

"Guillain-Barre syndrome"[MeSH Terms]

Reading File

I now have excellent, comprehensive content from multiple authoritative textbooks. Let me compile the full answer.

Guillain-Barré Syndrome (GBS)

Definition and Overview

Guillain-Barré syndrome is an acute, immune-mediated polyradiculoneuropathy of the peripheral nervous system. It is the leading cause of acute paralytic disease in Western countries since the eradication of poliomyelitis. Incidence is 0.81-1.89 per 100,000 per year worldwide, increasing with age and more prevalent in males (M:F = 1.5:1).

Bradley and Daroff's Neurology in Clinical Practice, p. 2663
Miller's Anesthesia, p. 12034

Subtypes and Variants

GBS is a heterogeneous syndrome. Classification is based on clinical, electrophysiological, and pathological findings:

Common Subtypes

Subtype	Features
AIDP (Acute inflammatory demyelinating polyradiculoneuropathy)	Most common in Europe/North America; demyelinating; classic ascending weakness
AMAN (Acute motor axonal neuropathy)	Pure motor; common in northern China, summer epidemics; linked to C. jejuni; anti-GM1/GD1a antibodies
AMSAN (Acute motor-sensory axonal neuropathy)	Both motor and sensory axons involved; severe, poor recovery

Rare Variants

Miller-Fisher Syndrome (MFS): Classic triad of ophthalmoplegia, ataxia, and areflexia; anti-GQ1b antibodies positive in 95-98% of cases; accounts for 6% of GBS in the West, up to 18% in Taiwan
Pharyngeal-cervical-brachial variant
Facial diplegia with paresthesias
Acute pandysautonomia
Bradley and Daroff's Neurology in Clinical Practice, p. 2663-2664

Pathophysiology

AIDP (Demyelinating)

Classic pathology shows endoneurial perivascular mononuclear cell infiltration with multifocal demyelination
Peripheral nerves affected at all levels from roots to distal intramuscular fibers
Injury most extensive in nerve roots and proximal nerve segments
Macrophage-rich mononuclear infiltrates are the hallmark

Axonal Forms (AMAN/AMSAN)

Autoimmune antibody response against gangliosides on the axolemma
C. jejuni molecular mimicry: LPS on the bacterium mimics GM1/GD1a gangliosides on peripheral nerve
AMAN: anti-GM1, anti-GD1a, anti-GalNAc-GD1a IgG antibodies
MFS: anti-GQ1b antibodies target cranial nerve gangliosides

Immune Mechanism

Both T-cell-mediated and antibody-mediated responses are involved; T cells are believed to play the dominant role
About two-thirds of cases are preceded by an infection triggering microbe-specific T cells and antibodies that cross-react with nerve sheath antigens
Robbins & Kumar Basic Pathology, p. 809
Bradley and Daroff's Neurology, p. 2663

Precipitating Factors

Agent	Notes
Campylobacter jejuni	Most common bacterial trigger; linked to AMAN variant
Cytomegalovirus (CMV)	Common viral trigger
Epstein-Barr virus (EBV)
Herpes simplex virus
HIV
Zika virus	Regional epidemic association
Chikungunya virus
SARS-CoV-2	Newly recognized association
Vaccinations	Non-infectious trigger
Immune checkpoint inhibitors	Non-infectious trigger

Symptoms begin 1-2 weeks after exposure, progress over several days, and peak at 2-4 weeks.

Clinical Features

Motor

Classic: ascending, symmetric weakness starting in the lower limbs and progressing proximally
Severity ranges from mild (ambulatory) to near-total quadriplegia
Hyporeflexia or areflexia - invariable features (may be absent early)
Respiratory failure requiring ventilation: 9-30% of patients (20-30% in AIDP)
In ~5%, progression is fulminant with maximal deficit within 72 hours

Cranial Nerve Involvement (45-75%)

Bilateral facial paresis - at least 50% of patients
Extraocular muscle involvement (less common)
Lower cranial nerve involvement: dysphagia, dysarthria

Sensory

Not prominent; distal vibration sense most affected
Pain (truncal, interscapular, extremities) in ~70% during acute phase - may persist a year in one-third
Dysesthetic pain (burning/tingling) is less common

Autonomic Dysfunction (65% admitted, ~20% ICU-significant)

Orthostatic hypotension
Urinary retention
Gastrointestinal atony
Episodic hypertension or sustained hypertension
Sinus tachycardia, tachyarrhythmias
Vagal spells: sudden bradycardia, heart block, asystole (may be triggered by tracheal suctioning)
ECG changes: T-wave abnormalities, ST depression, QRS widening, QT prolongation
Temperature dysregulation, anhidrosis or episodic diaphoresis
Bradley and Daroff's Neurology, p. 2665-2666
Miller's Anesthesia, p. 12035-12036

Diagnostic Criteria

Features REQUIRED for diagnosis:

Progressive weakness of both legs and arms
Areflexia or hyporeflexia

Clinical features SUPPORTIVE of diagnosis:

Progression over days to 4 weeks
Relative symmetry
Mild sensory symptoms or signs
Bifacial palsies
Autonomic dysfunction
Absence of fever at onset
Recovery beginning 2-4 weeks after progression ceases

Laboratory features SUPPORTIVE:

Elevated CSF protein with <10 cells/μL (albuminocytological dissociation)
Electrodiagnostic features of nerve conduction slowing or block
Bradley and Daroff's Neurology, p. 2664

Investigations

Test	Finding
CSF	Elevated protein, acellular (<10 cells/μL) - albuminocytological dissociation
Nerve Conduction Studies (NCS)	AIDP: prolonged distal latencies, slow CV, conduction block, absent F-waves; AMAN: low CMAP amplitudes, preserved CV
Anti-GQ1b antibodies	Positive in 95-98% of MFS
Anti-GM1, anti-GD1a	AMAN, associated with C. jejuni
ECG	Arrhythmias, T-wave changes
MRI spine + gadolinium	Cauda equina nerve root enhancement (especially in children); useful to exclude spinal cord disease
Pulmonary function	FVC, MIP - critical for ICU decision-making

Note on CSF: Pleocytosis >50 cells/μL should raise doubt about GBS and suggest Lyme, HIV, or CMV meningoradiculopathy.

Respiratory Monitoring (Critical)

Respiratory failure is the main indication for ICU admission. The "20-15-12 rule" (or similar thresholds in Miller's Anesthesia):

FVC < 20 mL/kg: Observe closely
FVC < 15 mL/kg: Consider intubation
MIP < -30 cmH2O: Impending failure
Hypercarbia is a LATE sign - do not rely on it

The EGRIS (Erasmus GBS Respiratory Insufficiency Score) is a validated tool to predict need for early ICU admission based on weakness severity, symptom timing, and bulbar symptoms.

Miller's Anesthesia, p. 12035

Differential Diagnosis

Category	Conditions
Spinal cord	Transverse myelitis, cord compression, anterior spinal artery syndrome
Brainstem	Basilar artery thrombosis, central pontine myelinolysis
Anterior horn cell	Poliomyelitis (wild-type, West Nile virus)
Peripheral nerve	Critical illness polyneuropathy, vasculitic neuropathy, heavy metal poisoning
NMJ	Myasthenic crisis, botulism, tick paralysis, organophosphates
Muscle	Polymyositis, critical illness myopathy
Metabolic	Severe hypokalemia, hypophosphatemia, hypermagnesemia

Key distinguishing clues:

Sensory level and early urinary retention = spinal cord (urgent MRI)
Normal CSF, axonal NCS pattern = critical illness polyneuropathy
CMAP decrement = myasthenic crisis
Incrementing response on high-frequency stimulation = botulism

Treatment

Specific Immunotherapy

Both are equally effective; no benefit from combining them:

Intravenous Immunoglobulin (IVIG) - suppresses immune response (mechanism unclear)
Plasmapheresis (plasma exchange) - removes offending antibodies

Sequential use (if one fails) is sometimes attempted by clinicians. Corticosteroids and interferon are NOT beneficial in GBS, either alone or in combination with immunotherapy.

ICU/Supportive Care

Mechanical ventilation for respiratory failure
DVT prophylaxis
Early mobilization and rehabilitation
Nutrition support and glucose control
Cardiac monitoring (autonomic dysfunction, arrhythmias)
Pain management: anticonvulsants are more effective than opiates for deafferentation pain
Psychosocial support (depression is common in cognitively intact, immobilized patients)
Miller's Anesthesia, p. 12036
Robbins & Kumar Basic Pathology, p. 809

Prognosis

Overall mortality: <3-5% (was 33% before modern critical care/positive-pressure ventilation)
Mortality with mechanical ventilation: 14.3%
Recovery begins 2-4 weeks after peak
Recovery may be protracted for months to years, especially with axonal injury
Poor prognostic factors:
- Axonal degeneration on NCS
- Anti-GM1 antibody positivity
- Persistent lack of foot flexion at end of immunotherapy
- Rapid progression, older age, need for ventilation

Summary Mnemonic

GBS = "Get Better Slowly"

Ganglioside antibodies (anti-GQ1b in MFS, anti-GM1 in AMAN)
Bacterial trigger (Campylobacter most common)
Symmetric ascending weakness + areflexia + albuminocytological dissociation

Sources: Bradley and Daroff's Neurology in Clinical Practice | Robbins & Kumar Basic Pathology | Miller's Anesthesia (10e)

Recent Evidence Update (2026): A 2026 systematic review (PMID: 41038424) found that physical exercise programs improve fatigue and functional capacity in GBS and CIDP - supporting early rehabilitation as part of management. No recent meta-analyses contradict current treatment guidelines on IVIG or plasmapheresis.

Side effects and adverse effects of rabies vaccine

Reading File

Finding Sources

Searching PubMed

"rabies vaccine"[MeSH Terms] AND "adverse effects"[MeSH Terms]

Reading File

Finding Sources

Reading File

I now have comprehensive, well-sourced data from four authoritative textbooks. Here is the complete answer:

Side Effects and Adverse Effects of Rabies Vaccine

Types of Vaccines (Context Matters)

There are two broad categories of rabies vaccines in use globally, with very different safety profiles:

Type	Examples	Safety
Cell culture vaccines (CCVs)	HDCV (Imovax), PCECV/RabAvert	Safe, well-tolerated
Nerve tissue-derived vaccines	Semple, Fuenzalida (used in some developing countries)	Serious neurological adverse effects

All US-licensed rabies vaccines are inactivated cell culture vaccines. Despite WHO warnings, some countries still manufacture nerve tissue-derived vaccines.

Rosen's Emergency Medicine, p. [3330-3336]

Cell Culture Vaccines - Adverse Effects

1. Local Reactions (Most Common)

Reaction	Incidence
Pain, swelling, redness, induration at injection site	60-85% with HDCV; 11-57% with PCECV
Pruritus at injection site	Common

These are the most frequently reported reactions and are generally mild and self-limiting.

2. Mild Systemic Reactions

Reaction	Incidence
Headache, nausea, abdominal pain, muscle aches, dizziness	6.8-55.6% (HDCV); up to 31% (PCECV)
Fever, myalgias	Reported with both vaccines

Management: Anti-inflammatory and antipyretic agents. Prophylaxis should NOT be stopped for local or mild systemic reactions.

3. Immune Complex-Like (Serum Sickness-Like) Reactions - HDCV Boosters

This is one of the more notable adverse effects:

Occurs 2 to 21 days after booster dose (not primary immunization)
Incidence: up to 6% of adults receiving HDCV booster doses (as part of pre-exposure prophylaxis regimen)
Rare after primary immunization; also reported with PCECV
Mechanism: likely due to interaction between beta-propiolactone (used to inactivate the vaccine) and human albumin in the vaccine, forming immune complexes

Features of this reaction:

Generalized urticaria (onset symptom)
Arthralgia and arthritis
Angioedema
Nausea and vomiting
Fever and malaise

Not life-threatening. If it occurs with HDCV, PCECV may be substituted on the same schedule (and vice versa). Pretreatment with antihistamines before the next dose can be considered for mild reactions.

4. Immediate Hypersensitivity / Anaphylaxis

Vaccine	Incidence
HDCV - previously unimmunized	1.2%
HDCV - booster (previously immunized)	Up to 6%
Anaphylaxis (any CCV)	Rare

Anaphylaxis is rare but does occur
Epinephrine must be readily available after every rabies vaccine dose
Patients should be observed for a period after injection
Severe egg allergy is a specific contraindication to PCECV (purified chick embryo cell vaccine)

5. Neurological Adverse Effects (Very Rare with CCVs)

Anaphylaxis and neurologic symptoms have only rarely been associated with current cell culture vaccines
No deaths have been reported from HDCV or PCECV recipients
The risk of neurological complications is incomparably lower than with nerve tissue vaccines

Nerve Tissue-Derived Vaccines - Adverse Effects (Severe)

These vaccines (not licensed in the US) contain myelin basic protein, which can trigger severe autoimmune responses:

Adverse Effect	Incidence/Notes
Neuroparalytic reactions	1 in 2,000 to 1 in 8,000 recipients
Postinfectious encephalomyelitis	Serious complication
Guillain-Barré Syndrome	Documented association
Transverse myelitis	Reported

Important: If meningeal or neuroparalytic reactions develop with nerve tissue vaccines, vaccination must be discontinued immediately. Corticosteroids should be used only for life-threatening reactions because they increase the risk of rabies in animal models.

Harrison's Principles of Internal Medicine 22E, p. 1699
Red Book 2021, p. 971

Adverse Effects of Rabies Immune Globulin (RIG)

RIG is administered alongside the vaccine in post-exposure prophylaxis (PEP). Its adverse effects are separate from the vaccine:

RIG Type	Adverse Effects
Human RIG (HRIG) - US standard	Uncommon serious effects; local pain and low-grade fever may occur
Equine RIG - used when human RIG unavailable	Low but higher rate of anaphylactic reactions and serum sickness (dose: 40 IU/kg)

Specific contraindication: HRIG should NOT be given to patients with IgA deficiency and known anti-IgA antibodies (small amounts of IgA in HRIG can cause severe allergic reactions).

Harrison's Principles of Internal Medicine 22E, p. 1698
Tintinalli's Emergency Medicine, p. 1096

Special Considerations

Situation	Guidance
Pregnancy	Not a contraindication; no association with spontaneous abortions, premature birth, or fetal abnormalities
Immunocompromised patients	5-dose PEP regimen; check neutralizing antibody titer 7-14 days after final dose
Corticosteroids/immunosuppressants	Reduce vaccine response; should not be used during PEP unless essential
Gluteal injection	Avoid - associated with rare vaccine failures and suboptimal antibody responses

Management of Adverse Reactions

Reaction Severity	Management
Local reactions, mild systemic	NSAIDs/antipyretics; do not stop PEP
Serum sickness-like (urticaria, arthralgia)	Antihistamines; consider switching vaccine brand
Serious hypersensitivity	Antihistamines; epinephrine on standby
Anaphylaxis	Epinephrine; hospitalization; weigh risk of rabies vs. continuing PEP
Nerve tissue vaccine - neuroparalytic	Discontinue vaccine immediately; corticosteroids only if life-threatening

Key principle: The risk of developing rabies always outweighs the risk of adverse vaccine reactions. Prophylaxis should generally be continued even when reactions occur, with appropriate symptom management.

Sources: Rosen's Emergency Medicine | Tintinalli's Emergency Medicine | Red Book 2021 (AAP) | Harrison's Principles of Internal Medicine 22E

Does it effect kidneys

Finding Sources

Searching PubMed

"rabies vaccine" AND "renal" OR "nephritis" OR "kidney"

Finding Sources

Searching PubMed

"rabies vaccine" AND "glomerulonephritis" OR "nephropathy"

Reading File

I now have enough to give a clear, evidence-based answer. The short answer is: no direct kidney toxicity, but there is an indirect, theoretical pathway via immune complex (serum sickness-like) reactions.

Does the Rabies Vaccine Affect the Kidneys?

The short answer: Not directly, and not as a recognized clinical adverse effect of modern cell-culture vaccines. However, there is one indirect mechanism worth understanding.

Modern Cell-Culture Vaccines (HDCV, PCECV)

There is no documented direct nephrotoxicity from current rabies vaccines. The textbooks covering rabies vaccine adverse effects - Rosen's, Tintinalli's, Harrison's, and the Red Book - do not list renal injury, nephritis, or kidney dysfunction among their adverse effects at all.

The Indirect Link: Serum Sickness-Like Reactions (Type III Hypersensitivity)

The one mechanism that could theoretically affect kidneys is the immune complex (Type III hypersensitivity / serum sickness-like) reaction seen with HDCV booster doses:

Occurs in ~6% of adults receiving HDCV boosters (rare with primary immunization)
Caused by beta-propiolactone (the virus-inactivating agent) chemically altering human albumin in the vaccine, creating a new antigen-antibody complex
Onset: 2 to 21 days after the booster dose
Symptoms: urticaria, arthralgia, arthritis, angioedema, nausea, vomiting, fever, malaise

Why kidneys are relevant here: Type III (immune complex) reactions as a class - which include serum sickness - are well-known to cause glomerulonephritis via deposition of immune complexes in the glomerular basement membrane. Classic examples of this mechanism include post-streptococcal GN, lupus nephritis, and Henoch-Schönlein purpura nephritis. The Red Book and immunology textbooks both list serum sickness as a recognized cause of glomerulonephritis.

However, the serum sickness-like reaction from the rabies HDCV booster is described as mild and not life-threatening in all sources, and kidney involvement from this reaction specifically has not been documented in the clinical literature reviewed.

Red Book 2021, p. 161-162
Quick Compendium of Clinical Pathology - Type III hypersensitivity

Nerve Tissue Vaccines - Greater Systemic Inflammation

Nerve tissue-derived vaccines (still used in some developing countries) cause far more severe systemic immune reactions, including neuroparalytic events and postinfectious encephalomyelitis. The broader, uncontrolled inflammatory response they trigger carries a higher theoretical risk of collateral organ involvement, including kidneys - but this is not specifically documented either.

Equine RIG - Relevant Caution

If equine rabies immune globulin (eRIG) is used instead of human RIG (in resource-limited settings), the risk of true serum sickness (with potential glomerulonephritis) is higher, since equine proteins are foreign antigens and can form immune complexes more robustly. The Harrison's text notes the incidence of anaphylactic reactions and serum sickness with recent equine RIG products is low, but it is a recognized risk.

Harrison's Principles of Internal Medicine 22E, p. 1698

Summary

Vaccine/Product	Kidney Effect
HDCV / PCECV (modern CCVs)	No direct kidney toxicity documented
HDCV booster serum sickness-like reaction	Theoretical glomerulonephritis risk via immune complexes, not documented clinically
Nerve tissue vaccines	Severe systemic inflammation; kidney involvement not specifically documented
Equine RIG	Low risk of serum sickness with potential (rare) renal involvement

Bottom line: Kidney effects from rabies vaccination are not a recognized or reported adverse effect of current cell-culture vaccines. If you or a patient experienced any urinary symptoms, swelling, or reduced urine output after a rabies vaccine, that would be unusual and should be investigated by a doctor - but it is not an expected effect of the vaccine.

Sources: Rosen's Emergency Medicine | Red Book 2021 (AAP) | Harrison's Principles of Internal Medicine 22E | Katzung's Pharmacology

This is a shared conversation. Sign in to Orris to start your own chat.